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Basal-like breast cancers (BLBC) are characterized by defects in homologous 53 
recombination (HR), deficient mitotic checkpoint, and high proliferation activity. Here, we 54 
discover CIP2A as a candidate driver of BLBC. CIP2A was essential for DNA-damage-55 
induced initiation of mouse BLBC-like mammary tumors and for survival of homologous 56 
recombination defective (HRD) BLBC cells. CIP2A was dispensable for normal mammary 57 
gland development and for unperturbed mitosis, but selectively essential for mitotic 58 
progression of DNA-damaged cells. A direct interaction between CIP2A and a DNA repair 59 
scaffold protein TopBP1 was identified and CIP2A inhibition resulted in enhanced DNA 60 
damage-induced TopBP1 and RAD51 recruitment to chromatin in mammary epithelial 61 
cells. In addition to its role in tumor initiation, and survival of BRCA-deficient cells, CIP2A 62 
also drove proliferative MYC and E2F1 signaling in basal-like triple negative breast cancer 63 
(BL-TNBC) cells. Clinically, high CIP2A expression was associated with poor patient 64 
prognosis in BL-TNBCs but not in other breast cancer subtypes. Small molecule 65 
reactivators of PP2A (SMAPs) inhibited CIP2A transcription, phenocopied the CIP2A-66 
deficient DNA damage response (DDR), and inhibit growth of patient-derived BLBC 67 
xenograft. In summary, these results demonstrate that CIP2A directly interacts with 68 
TopBP1 and coordinates DNA-damage induced mitotic checkpoint and proliferation, 69 
thereby driving BLBC initiation and progression. SMAPs could serve as a surrogate 70 
therapeutic strategy to inhibit the oncogenic activity of CIP2A in BLBCs. 71 
Significance: These results identify CIP2A as a non-genetic driver and therapeutic target 72 
in basal-like breast cancer that regulates DNA-damage-induced G2/M checkpoint and 73 
proliferative signaling. 74 
Keywords: ATR, RHNO1, Nibrin, Double stranded DNA break, DT-061  75 
Research. 
on October 6, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 18, 2021; DOI: 10.1158/0008-5472.CAN-20-3651 
   
 





One of the most aggressive and clinically challenging breast cancer subtypes is the basal-78 
like breast cancer (BLBC)(1-3). Based on transcriptional signatures of the breast cancer 79 
subtypes (4), the hallmarks of BLBCs are high proliferation activity, G2/M checkpoint 80 
dysregulation, ATR/BRCA pathway activity, and high DNA replication. Additionally, 81 
molecular characteristics of BLBCs include high genetic instability, BRCA mutations, TP53 82 
inactivation, and dysregulation of EGFR (1-4). About 75% of BLBCs belong to the triple-83 
negative breast cancer subtype (BL-TNBCs), devoid of ER, PR and HER2 (1). In addition 84 
to their frequently aggressive clinical appearance, the lack of these targetable receptors 85 
makes BLBCs therapeutically very challenging. Despite the near saturated genetic 86 
knowledge of breast cancer, like some other subtypes as well, no clear genetic oncogenic 87 
drivers have been identified for the BLBCs (1,3).   88 
 89 
Among the breast cancer subtypes, BLBCs have the highest mutational burden as a result 90 
of acquisition of BRCA mutations, or other defects in the homologous recombination (HR) 91 
pathways (1-4).  Normal HR proficient cells respond to double stranded DNA breaks (DSB) 92 
by activating the G2/M cell cycle checkpoint resulting in mitotic arrest (5). To allow mitotic 93 
progression under DNA damaging conditions, transformed cells instead have developed 94 
strategy to dampen G2/M checkpoint signaling (5,6). Based on the high mutational burden 95 
observed in BLBC, it could be hypothesized that a potential BLBC driver mechanism has 96 
the ability to coordinately dampen the DNA-damage induced G2/M checkpoint, and to 97 
support high proliferation activity in premalignant mammary epithelial cells.  One of the 98 
DDR proteins involved in G2/M checkpoint signaling is DNA Topoisomerase II binding 99 
protein 1 (TopBP1)(7), which is a scaffold protein that interacts with the checkpoint kinase 100 
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ATR (8). In the presence of DSBs, TopBP1 promotes RAD51 chromatin loading resulting 101 
in G2/M arrest (9-12). RAD51 foci formation has been associated in BLBCs as a marker of 102 
BRCA deficiency and HR impairment (4,13). These features make TopBP1-mediated 103 
RAD51 regulation a candidate G2/M checkpoint mechanism in BLBC (5,7,10).  104 
 105 
Recently the serine/threonine phosphatase PP2A has gained attention as a druggable 106 
tumor suppressor (14-16). Of specific relevance to this work, is the role of serine/threonine 107 
phosphatases in the DNA damage response at chromatin (6),  which could link them to 108 
cancer types with homologous recombination defects, and high mutational burden, such 109 
as BLBCs. PP2A is inhibited in most cancers by non-genetic mechanisms including high 110 
expression of endogenous inhibitor proteins such as CIP2A, PME-1 or SET, or changes in 111 
carboxymethylation to the C terminal tail of the catalytic domain (15,17). CIP2A is 112 
expressed at low levels in normal mammary gland tissue (18). However, CIP2A 113 
transcription is induced by TP53 mutation via increased E2F1 activity (18,19), and by 114 
EGFR pathway activation (20,21), features closely linked to BLBC (1). However, it is 115 
currently unclear what role CIP2A plays in BLBC initiation, or progression. Notably, 116 
understanding of CIP2A-related cancer initiation mechanisms is also therapeutically 117 
relevant due to the recent development of small molecule activators of the CIP2A-inhibited 118 
PP2A-B56 heterotrimer that demonstrate potent antitumor activities (14,16).  119 
 120 
In this study, we provide the first evidence for an essential role for CIP2A in tumor initiation 121 
in cancer. Specifically, we demonstrate by using both chemical and transgenic tumor 122 
models that CIP2A is essential for the initiation of mouse BLBC tumors, but not for the 123 
initiation of skin, ovarian, lung or stomach tumors. Furthermore, among transformed breast 124 
cancer cell types, CIP2A is essential for survival of BRCA/TP53-mutant BLBC cells. 125 
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Mechanistically, the role for CIP2A in driving BLBC initiation and progression can be 126 
explained by its capacity to coordinately regulate key BLBC hallmarks; specifically the 127 
G2/M checkpoint and cellular proliferation. Molecularly we discover direct CIP2A 128 
interaction with TopBP1 and provide evidence for CIP2A-mediated inhibition of both 129 
TopBP1 and RAD51 recruitment to chromatin upon DNA-damage in premalignant 130 
mammary epithelial cells. CIP2A also promotes pro-proliferative MYC and E2F1 activities 131 
in BLBC cells. Finally, we discover that small molecules shown previously to activate 132 
PP2A (16,22),  transcriptionally inhibit CIP2A expression, and serve as candidate 133 
therapeutics for CIP2A-positive BLBCs.  134 
 135 
  136 
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Materials and Methods 137 
 138 
Mouse experiments 139 
All animal work protocols were approved either by the Project Authorisation Board of the 140 
Regional State Administrative Agency for Southern Finland, the Animal Ethics Committee 141 
of the Netherlands Cancer Institute or the Institutional Animal Care and Use Committee at 142 
the Case Western Reserve University, which is certified by the American Association of 143 
Accreditation for Laboratory Animal Care under protocol # 2013-0132. 144 
 145 
For DMBA-induced tumors in WT and Cip2a-/- female mice, several independent cohorts 146 
of the mice were administered with 1mg of DMBA dissolved in 200µl of corn oil by oral 147 
gavage once a week for 6 weeks starting at 12-14 weeks of age as previously described 148 
(23). The mice were monitored twice a week for tumor formation until morbidity. Mice were 149 
sacrificed upon tumor burden and/or when they showed general signs of illness. For 150 
DMBA-induced mutation load and Cip2a mRNA expression in WT and Cip2a-/- 151 
premalignant mammary gland tissues, the mice were sacrificed 2 weeks after the last 152 
DMBA treatment. DMBA/TPA protocol for skin tumorigenesis and experiments with Cip2a-153 
/- mice crossed with an ovarian cancer mouse model TgMISIIR-Tag are described in 154 
supplementary materials and methods. Tissue samples collected for extraction of RNA 155 
and genomic DNA were snap frozen into liquid nitrogen. Tissue samples for histochemical 156 
and for immunohistochemical analysis were fixed in formalin. 157 
 158 
Mouse tumor cell lines were generated from spontaneous mammary tumors of following 159 
breast cancer mouse models: K14Cre; Brca1F/F; Trp53F/F(KB1P) (24), K14Cre; Cdh1F/F; 160 
Trp53F/F(KEP) (25) and Wap-cre; Cdh1F/F; Akt1E17K(WEA) (26). Tumor cell lines were 161 
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generated by collecting tumors in cold PBS and minced by chopping with scalpels. 162 
Aggregates were plated out. KEP and WEA tumor cell line cultures were incubated at 163 
37C with 5% CO2 and 20% O2. KB1P cell lines were incubated at 37C with 5% CO2 and 164 
3% O2. Homogenous epithelial cell morphology was obtained after cultures were 165 
passaged 2-3 times. Used cell culture media are described in Table S1. 166 
 167 
Analysis of human breast cancer patient sample cohorts 168 
FinHer study (HUCH 426/E6/00) was approved by an ethics committee of the Helsinki 169 
University Central Hospital (Helsinki, Finland). Study participants provided written informed 170 
consent before study entry. The study was conducted in accordance of the Declaration of 171 
Helsinki. The role of CIP2A in disease-free survival of breast cancer patients in the 172 
GSE21653 cohort was analyzed by using an online platform ‘R2: Genomics Analysis and 173 
Visualization Platform’ (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). More detailed 174 
description of analysis of both cohorts can be found from supplemental data. 175 
 176 
Cell culture and transfections 177 
All the commercial cell lines used in this paper were purchased from American Type 178 
Culture Collection (ATCC) or Leibniz Institute’s German Collection of Microorganisms and 179 
Cell Cultures (DSMZ). All the cells in culture were negative on periodically testing for 180 
mycoplasma using Mycoplasma Detection Kit (Roche). All the human and mouse cells, 181 
their culture conditions and supplements used for cell culture are listed in Table S1. Breast 182 
cancer stem-like cells (BCSCs) were isolated from TNBC patients who received standard 183 
chemotherapy and cultured as described previously (27).  184 
 185 
Antibodies, RNAs, primers, DNA constructs and drugs. 186 
Research. 
on October 6, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 18, 2021; DOI: 10.1158/0008-5472.CAN-20-3651 
   
 
   
 
9 
Antibodies (along with dilutions for each application), plasmids and sequences of siRNAs, 187 
gRNAs and primers used are listed in Table S2. All chemical inhibitors and drugs used are 188 
listed in the Table S3. 189 
 190 
Mitotic index experiments 191 
Mitotic index experiments were conducted by modifying previously published protocol 192 
described in (7). Briefly, MCF10A cells were transfected with indicated siRNAs for 24 193 
hours, following which they were seeded into ibidi 8 well μ slides (ibiTreat #80826) for 24 194 
hours. Cells were irradiated with 10Gy radiation followed by Nocodazole block (100ng/ml), 195 
one hour after IR for 18 hours. After the indicated time points, cells were stained for 196 
phospho-Histone H3 (Ser10) using similar immunofluorescence protocols as mentioned 197 
above. Images were taken on Zeiss Axiovert or EVOS fl Microscope with 10X objective 198 
and quantified using ImageJ software (RRID:SCR_003070). Experiment was repeated 3 199 
times. 200 
  201 
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Cip2a is selectively required for initiation of DMBA-induced mammary tumors in 203 
mice 204 
To address whether CIP2A is truly essential for the initiation of cancer in vivo, we 205 
challenged several independent cohorts of the previously described Cip2a-/- mice (19,28) 206 
with a chemical carcinogenesis protocol consisting of six consecutive doses of the 207 
genotoxic agent 7,12-dimethylbenz[a]anthracene (DMBA) (Fig. 1A). Similar to other 208 
polyaromatic hydrocarbons, DMBA forms covalent DNA adducts, and induces a DNA 209 
damage response (DDR) including activation of ɣH2AX, ATR, and RAD51 (29). Oral 210 
exposure of mice to DMBA induces mouse BLBCs (23), but also several other cancers, 211 
allowing us to assess the relative importance of Cip2a to tumor development across 212 
different cancer types. As compared to a model combining DMBA and 213 
medroxyprogesterone acetate (MPA), the DMBA-only mammary tumors are initiated with 214 
much longer latency (23). Importantly, the tumor initiating cell type of mammary tumors 215 
induced by DMBA-only is basaloid cells, and molecularly these tumors faithfully resemble 216 
human BLBCs (23).  217 
 218 
As expected (29), DMBA treatment induced a significant increase in the mutational load in 219 
non-tumorigenic mammary gland tissue as soon as only 2 weeks after the last DMBA 220 
dose; however the mutational load (Fig. 1 B and Table S4), or overall survival (Fig. S1A) 221 
was not associated with the Cip2a genotype. When assessed by palpation, external 222 
observation, and by tissue pathology analysis upon autopsy of the mice with any 223 
symptoms of reduced well-being, tumors in five different tissue types were observed in the 224 
DMBA-treated mice (Fig. 1C). Notably, while incidence of tumors in ovary, lung, skin or 225 
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stomach were not altered in Cip2a-/- mice, mammary tumors showed almost absolute 226 
dependence on Cip2a for tumor initiation (Fig. 1C, D and S1B).  227 
 228 
To control for the possibility that lack of genotype dependence of other cancer types on 229 
Cip2a was a result of leakage of the genetrap cassette used for Cip2a gene silencing (28), 230 
we confirmed the absence of CIP2A protein expression in ovarian cancer tissues from 231 
Cip2a-/- mice (Fig. S1C). We further confirmed that Cip2a was dispensable for skin and 232 
ovarian tumorigenesis by independent in vivo models. To this end, we crossed Cip2a-/- 233 
mice with the MISIIR-Tag mouse model producing tumors resembling high grade ovarian 234 
cancer (30), and did not observe any notable difference in ovarian tumorigenesis between 235 
Cip2a wild-type (WT) or Cip2a-/- mice by PET/CT-imaging or by visual inspection after 236 
autopsy (Fig. S1D,E). For the skin tumorigenesis model, we used a classical DMBA/TPA 237 
two-stage skin tumorigenesis protocol and again did not observe any differences in skin 238 
tumor initiation between the Cip2a genotypes (Fig. S1F).  239 
 240 
Combined, these results in multiple independent in vivo models strongly suggest that 241 
CIP2A is required for the propagation of DNA-damaged mammary basaloid epithelial cells. 242 
To validate that this is a cell intrinsic property of CIP2A, we tested the impact of CIP2A 243 
silencing on mitotic progression of MCF-10A basal like immortalized mammary epithelial 244 
cells treated with ionizing radiation (IR). Notably, whereas inhibition of checkpoint kinase 245 
CHK1 abrogated the G2/M checkpoint and CIP2A silencing did not impact mitotic 246 
progression of untreated MCF-10A cells, CIP2A was found to be indispensable for G2/M 247 
progression in IR-treated MCF10A cells (Fig. 1E and S1G).  To provide independent 248 
validation to these results, we surveyed results from a genetic screen in HAP1 cells (31) 249 
(see Fig. S1H for technical description). Directly supportive of the role for CIP2A in 250 
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allowing cell propagation under DNA damage, CIP2A was the only tested PP2A inhibitor 251 
protein that was essential under repeated low-dose irradiation (Fig. 1F).  252 
 253 
These results establish essentiality for Cip2a for the initiation of DNA-damage induced 254 
mammary tumors previously confirmed to faithfully represent mouse BLBCs (23). As such 255 
the results represent the first evidence for a critical role for CIP2A in tumor initiation.  256 
 257 
Cip2a is induced by DMBA in premalignant mammary gland tissue and drives 258 
initiation of mouse BLBC-like tumors 259 
A key criterion for a cancer driver candidate involved in tumor initiation, is expression in 260 
premalignant tissue prior tumorigenesis. Consistent with negligible CIP2A protein 261 
expression in normal human mammary glands (18), Cip2a mRNA was expressed at a very 262 
low level in WT mouse mammary glands (Fig. 2A). Importantly, non-tumorous WT 263 
mammary glands sampled 2 weeks after the last dose of DMBA (Fig. 1A) displayed 264 
significantly increased Cip2a mRNA expression (Fig. 2A).  In line with a suggested role as 265 
a disease driver, Cip2a mRNA expression was induced significantly more in mammary 266 
tumors from DMBA-treated WT mice (Fig. 2A). However, as mammary tumors were 267 
induced in only some of the mammary glands in each of the DMBA-treated WT mice, we 268 
conclude that Cip2a expression is essential, but not sufficient alone to induce 269 
tumorigenesis.  270 
 271 
Based upon the molecular characterization of the mammary tumors from DMBA-treated 272 
WT mice, the majority of the characterized tumors had BLBC or BL-TNBC phenotypes 273 
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(Fig. 2B,C and S2A). This is consistent with a previous report demonstrating that the tumor 274 
initiating cells from this DMBA model are of basaloid origin (23). The small number of 275 
estrogen receptor (ER) positive tumors observed is consistent with TCGA data that about 276 
10% of human BLBCs are ER positive. Furthermore, although use of different DMBA in 277 
vivo protocol was recently shown to result in ER positive tumors (32), it was demonstrated 278 
by using the DMBA protocol used in our study that serial transplantation of ER positive 279 
tumors yielded ER negative secondary tumors, suggesting that ER expression was not a 280 
driver mechanism in these tumors (23). To study the impact of Cip2a on DMBA-induced 281 
mammary gland gene expression profiles, we performed RNA-sequencing analysis of non-282 
tumorigenic mammary glands from mice housed for more than 4 months after the last 283 
dose of DMBA. Fully consistent with basaloid and HRD phenotype, Cip2a was found to 284 
control G2/M checkpoint, and proliferative signaling via the MYC and E2F1 pathways (Fig. 285 
2D). The tumors in WT mice were also highly proliferative based on Ki67 staining, and 286 
displayed both CIP2A and MYC protein overexpression potentially indicative of their 287 
known feed-forward regulatory loop (33)(Fig. 2B).  Evaluating the CIP2A positivity in 288 
DMBA-treated pre-tumorigenic mammary gland duct epithelial cells and from mammary 289 
tumors in WT mice, revealed predominantly cytoplasmic, but also nuclear CIP2A protein 290 
expression (Fig.S2B). This pattern is consistent with previous analysis indicating that there 291 
is a small pool of nuclear CIP2A in propagating cells (34), and indicate a potential function 292 
for nuclear CIP2A in early mammary tumorigenesis. Notably, the lack of predominantly 293 
BLBC tumors in Cip2a-/- mice was not related to any genotype-associated alterations in 294 
the basal and luminal epithelial cell ratio in the mammary gland (Fig. S2C-F). Furthermore, 295 
we did not observe any notable differences in the mammary gland development and 296 
branching morphogenesis between WT and Cip2a-/- mice (Fig. S2G).  297 
 298 
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Collectively, these results demonstrate that although Cip2a is dispensable for normal 299 
mouse mammary development, DMBA-elicited induction of Cip2a mRNA expression is 300 
required for initiation of mouse BLBC-like tumors.  301 
 302 
Co-dependence analysis reveals a functional association between CIP2A, TopBP1 303 
and G2/M checkpoint regulation 304 
 305 
Although our results strongly indicate that the previously reported CIP2A-MYC feed-306 
forward loop (33,35,36) is highly relevant for proliferation in DMBA-induced BLBCs (Fig. 307 
2B and S2A), MYC regulation is unlikely to explain either the newly discovered role for 308 
CIP2A in G2/M checkpoint regulation (Fig. 1E,F and S2A), or its essentiality for in vivo 309 
propagation of DNA-damaged mammary epithelial cells (Fig. 1C,D and S2G). 310 
Furthermore, as TPA/DMBA-induced skin tumorigenesis is dependent on MYC (37), but 311 
totally independent of CIP2A (Fig. S1F), we hypothesized that CIP2A is involved in the 312 
regulation of a yet uncharacterized MYC-independent, but HRD-related mechanism. To 313 
identify such mechanism in an unbiased manner, we surveyed a CRISPR/Cas9-based 314 
dropout screen repository from DepMap (Avana 2020 Q1; https://depmap.org), to identify 315 
genes that are most significantly similar in their essentiality with CIP2A.  316 
 317 
Remarkably, across 739 human cancer cell lines all the top 10 co-dependent genes with 318 
CIP2A (i.e. functionally most similar to CIP2A) were DDR genes (Fig. 3A). Notably, out of 319 
these top ten CIP2A-associated DDR factors, CIP2A was at the genome-wide level the 320 
most significantly similar gene for RHNO1, TOPBP1, POLQ, NBN and PARP1 (Fig. 3A). In 321 
the case of TOPBP1, the co-dependency with CIP2A was greater than with ATR (Fig. 3B), 322 
which is the bona-fide TopBP1 DDR effector (7,8). On the other hand, strongly supporting 323 
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the selectivity of CIP2A´s association with DDR mechanisms, and arguing against MYC 324 
being the sole effector of CIP2A in tumorigenesis, there was no overlapping genes found 325 
among the top ten co-dependent genes between CIP2A and MYC (Fig. 3A and S3A).     326 
 327 
When analyzed for functional protein association networks by STRING database 328 
(https://string-db.org), the top CIP2A-associated proteins (Fig. 3A) formed a tight protein 329 
network (Fig. 3C), that was functionally linked with HRD-associated processes such as 330 
“G2/M DNA damage checkpoint”, “Homology directed Repair”, and “Processing of DNA 331 
double-strand break ends” (Fig. 3D). Interestingly, in a recent PP2A-related 332 
phosphoproteome survey (38), CIP2A was found to prevent the dephosphorylation of 333 
Nibrin (NBN), which was one of the TopBP1 protein network members (Fig. 3C). NBN is 334 
known to co-operate with TopBP1 in ATR activation, and dephosphorylation of serine 432 335 
of NBN, as observed in CIP2A depleted cells (Fig. S3B)(38), impairing cell survival under 336 
IR (39). CIP2A was also recently found to be a NBN co-dependent gene in PARP inhibitor 337 
treated cells (40).    338 
 339 
Additional evidence for the intertwining of CIP2A with the TopBP1 complex was obtained 340 
by mRNA co-expression analysis across 1156 cell lines from the Broad institute Cancer 341 
Cell line Encyclopedia. Of the CIP2A co-dependent genes (Fig. 3A), TOPBP1 and POLQ 342 
were also among the 25 most significantly co-expressed genes with CIP2A (Fig. 3E and 343 
Fig. S4A). Both TOPBP1 and POLQ showed very significant co-expression with CIP2A 344 
also when only the BLBC cell lines were surveyed (Fig. S4B). The DepMap co-345 
dependence data was also utilized to understand the interesting difference in CIP2A 346 
dependence in the initiation of mammary and ovarian cancers (Fig. 1). To this end, we 347 
analyzed in a pair-wise fashion the correlation between dependence on either CIP2A, or 348 
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one of the functionally most similar genes RHNO1, TOPBP1, POLQ, NBN and PARP1 349 
(rank 1 genes from Fig. 3A) across either BLBC or HGSOC cell lines. TOPBP1 and NBN 350 
had higher co-dependence with CIP2A in BLBC than in HGSOC cells, while in HGSOC, 351 
RHNO1 was more co-dependent with CIP2A (Fig. 3F). These differences may provide one 352 
plausible explanation for the differential requirement of Cip2a for DMBA-induced BLBC-353 
like, but not ovarian cancer initiation (Fig. 1C, and S1B). Notably, TOPBP1 did not show 354 
CIP2A co-dependence in HGSOC cells, but was co-dependent in BLBC cells (Fig. 3F).  355 
 356 
CIP2A dampens TopBP1-RAD51 function under DNA damage 357 
 358 
Although the results above identify a potential novel role for CIP2A in TopBP1-complex 359 
mediated G2/M arrest, there is currently no evidence for a direct mechanistic link between 360 
CIP2A and TopBP1. Here, by using a genome-wide Y2H assay with a human breast 361 
cancer cDNA library, TopBP1 was identified with very high confidence as an interaction 362 
partner for CIP2A (Fig. 4A) (Table S5). As Y2H assay only detects direct interactions 363 
between two proteins, we conclude that the CIP2A-TopBP1 association does not involve 364 
PP2A. However, as indicated by NBN phosphorylation data (38)(Fig. S3B), CIP2A may still 365 
protect proteins in the TopBP1 complex from PP2A-mediated dephosphorylation.  366 
 367 
CIP2A is predominantly a cytoplasmic protein, but based on our current (Fig. S2B) and 368 
previous data (34), there is also a nuclear CIP2A pool in propagating cells in vitro and in 369 
vivo. Interaction between TopBP1 and endogenous nuclear CIP2A was confirmed from 370 
propagating cells by co-immunoprecipitation and proximity ligation analysis (Fig. 4B and 371 
S5A). H2AX also co-immunoprecipitated with TopBP1 and CIP2A from DNAse treated 372 
cellular lysates indicating that direct TopBP1-CIP2A interaction occurs at chromatin (Fig. 373 
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4B). By narrowing down the minimal shared region between TopBP1 fragments interacting 374 
with CIP2A in the Y2H assay, the interaction with CIP2A was delineated to be mediated by 375 
the stretch of amino acids 829-853 located between 5th and 6th BRCT domain of TopBP1 376 
(Fig. 4A, Table S5). The region between the 5th and 6th BRCT domain was also essential 377 
for interaction by co-immunoprecipitation analysis (Fig. 4C,D). Notably, the interaction was 378 
greatly strengthened by the presence of the ATR-activation domain (AAD) of TopBP1 379 
adjacent to 6th BRCT repeat (Fig. 4C,D).  As, no other DNA repair related proteins were 380 
identified in CIP2A Y2H screen (Table S5), the results support a model where direct 381 
binding to the scaffold protein TopBP1 mediates CIP2A interaction with the DDR network. 382 
 383 
Directly linking CIP2A to TopBP1-regulated DDR, CIP2A inhibition significantly increased 384 
ATR phosphorylation in the propagating premalignant mammary cell line MCF-10A (Fig. 385 
4E), and the highest phosphorylation of the ATR target H2AX (H2AX)(41) was observed 386 
in CIP2A-depleted cells overexpressing AAD variant of TopBP1 (Fig. 4F). The role of 387 
CIP2A in dampening IR-induced H2AX was validated in primary mammary epithelial cells 388 
isolated from WT and Cip2a-/- mice (Fig. S5B). Although PP2A has been validated as a 389 
H2AXphosphatase in replication stressed cells (42), we interpret that increased H2AX 390 
phosphorylation in CIP2A depleted replicating cells is rather due to increased TopBP1-391 
associated ATR activity (7,8,41). Further supporting the role of CIP2A in dampening 392 
TopBP1 function, CIP2A depletion in IR-treated proliferating cells resulted in significantly 393 
enhanced chromatin recruitment of TopBP1 (Fig. 4G,H). This was specific to TopBP1, as 394 
CIP2A did not impact IR-induced p53BP1 chromatin recruitment (Fig. S5C). As CIP2A 395 
depletion did not induce ATM phosphorylation (Fig. S5D) which is a known mechanism 396 
increasing TopBP1 chromatin recruitment (8), we postulate that CIP2A prevents TopBP1 397 
chromatin binding by direct interaction with its BRCT-domains (Fig. 4A). In BRCA wild-type 398 
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cells TopBP1 mediates G2/M arrest in response to IR by promoting RAD51 chromatin loading 399 
(10-12,43).  Consistent with the G2/M arrest phenotype (Fig. 1E and 2D), and increased 400 
TopBP1 foci formation (Fig. 4G,H), the Cip2a-/- mammary epithelial cells exposed to IR 401 
displayed significantly enhanced RAD51 chromatin recruitment 2 hours after irradiation 402 
(Fig. 4I,J).  Importantly, increased RAD51 retention at chromatin was observed still 6 hours 403 
after irradiation in Cip2a-/- mammary epithelial cells, indicating for a long-term defect in 404 
DNA repair foci clearance (Fig. S5E). 405 
 406 
Together with the established role for TopBP1/RAD51 complex in DNA damage-induced 407 
G2/M checkpoint activity (7,9-11,43), the discovered CIP2A-mediated inhibition of TopBP1 408 
and RAD51 chromatin recruitment provides a mechanism for dampening of the G2/M 409 
checkpoint in CIP2A-positive premalignant mammary epithelial cells (Fig. 4K).  410 
 411 
CIP2A is essential for survival of TP53/BRCA-mutant BLBC cells  412 
 413 
Next, we assessed whether the role of CIP2A as a mouse BLBC driver candidate 414 
translates to human BLBC. Firstly, both CIP2A and TOPBP1 mRNA was found to be 415 
highest expressed in BLBC across the human breast cancer subtypes (Fig. 5A and 416 
S6A,B). TP53 mutations in BLBC may result in activation of CIP2A gene promoter activity 417 
through the p21-E2F1 pathway (19) and accordingly, a significant correlation between 418 
TP53 mutation, and high CIP2A expression was confirmed in the GSE21653 cohort (Fig. 419 
S6C). The clinical relevance and selectivity of CIP2A for human BLBC was evident from 420 
patient survival analysis. Both high mRNA and protein expression of CIP2A predicted poor 421 
disease-free and overall survival only in BL-TNBC, but not in non-BL-TNBC breast cancers 422 
(Fig. 5B-E, and S6D-H). CIP2A neither had a predictive role among patients with ER-423 
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positive tumors, or in unselected breast cancers (Fig. S6D,G). Notably, the 5-year survival 424 
of patients with highly CIP2A positive BL-TNBC tumor was only about 50% in both patient 425 
cohorts (Fig. 5B, D), indicating that these high CIP2A tumors are particularly aggressive. 426 
Furthermore, high CIP2A expression significantly associated with mutation load in TNBC 427 
tumors based on TCGA data (Fig. S6I). This finding indicates that while CIP2A expression 428 
is not impacting mutation frequency per se (Fig. 1B), it allows survival of DNA-damaged 429 
cells (Fig. 1F), and thereby accumulation of tumor mutational load in fully developed 430 
TNBCs.  431 
 432 
To assess the BLBC cell dependence on CIP2A, we surveyed the Dep-Map essentiality 433 
database across 33 breast cancer cell lines. Among the 12 cell lines with CERES gene 434 
dependency score less than -0.4 for CIP2A loss, the great majority of cell lines were found 435 
to be BLBC cells (Fig. 5F, Table S6). Notably, all except one of these most CIP2A-436 
dependent BLBC cells carried either a BRCA1 or BRCA2 mutation which is a hallmark of 437 
BLBCs (Fig. 5F).  Furthermore, in a genetically defined CRISPR/Cas9 model, Cip2a was 438 
found to be essential for colony growth of mouse mammary tumor cells depleted for Trp53 439 
and Brca1 (KB1P; basal-type)(24)(Fig. 5G). However, Cip2a was dispensable for growth of 440 
either Trp53/E-cadherin mutant mammary tumor cells (KEP; invasive lobular carcinoma-441 
type)(25)(Fig. 5G), or cells from the mice with activated AKT and loss of E-cadherin in 442 
mammary tumor cells (WEA; invasive lobular carcinoma-type)(26)(Fig. S7A). Furthermore, 443 
RNA-sequencing analysis from the most CIP2A-dependent TP53-mutant BLBC cell line 444 
(Fig. 5H, S7B) and HCC38 (TP53 mutant/BRCA1 promoter methylation/BRCA2 mutant), 445 
revealed that CIP2A drove similar BLBC and HRD-associated gene expression programs 446 
as was observed from DMBA-treated mouse mammary tissue (Fig. 2D and Fig. 5I). The 447 
role of CIP2A in inhibiting the dephosphorylation of the activating phosphorylation sites in 448 
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both MYC and E2F1 was confirmed by western blot analyses (Fig. 5J). Finally, consistent 449 
with recent identification of CIP2A as an essential gene in PARP inhibitor talazoparib-450 
treated cells (40), CIP2A depletion hypersensitized BRCA-proficient MDA-MB-231 cells to 451 
two different PARP inhibitors (Fig. S7C). 452 
 453 
These data reveal essentiality of CIP2A for the survival BRCA-deficient BLBC cells, and 454 
thus fully support the mouse data indicating the driver role of CIP2A in BLBC. Clinically the 455 
data introduces CIP2A as a potential biomarker to identify BL-TNBC patients with 456 
particularly aggressive disease.  457 
 458 
 459 
Transcriptional CIP2A targeting by SMAPs as potential BLBC therapy 460 
 461 
Effective treatment of BLBCs represents a significant unmet medical need. As our data 462 
indicate that CIP2A regulates PP2A activity towards both the TopBP1 complex (Fig. 3C 463 
and S3B), as well as towards MYC and E2F1 (Fig. 5J), we tested whether a recently 464 
developed series of Small Molecule Activators of PP2A (SMAPs) (14,16), could be used to 465 
target CIP2A-expressing BLBC. SMAPs activate the CIP2A-regulated PP2A-B56alpha 466 
heterotrimer (14,44), and the cellular effects of SMAPs in cancer cells are both correlated 467 
with PP2A reactivation capacity, and can be rescued by concomitant PP2A inhibition 468 
(22,45).  469 
 470 
Treatment with two independent SMAPs (DBK-1154 and DT-061) resulted in a robust 471 
inhibition of cell viability in eight established BL-TNBC cell lines (Fig. 6A and S8A), and in 472 
five BLBC patient-derived cancer stem cell-like lines (27)(Fig. 6B). Notably, consistent with 473 
notion that these cell lines were derived from tumors of patients that had undergone 474 
neoadjuvant chemotherapy, these CIP2A positive (Fig.  S8B) patient-derived BLBC cell 475 
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lines showed resistance to classical chemotherapies (Fig. 6B). Directly supportive of the 476 
therapeutic relevance of these observations, oral DT-061 therapy resulted in significant 477 
inhibition of tumor growth of an orthotopic PDX model from a patient with TP53 mutant, 478 
EGFR+ BLBC over a 40-day treatment period (Fig. 6C). Similar to other in vivo studies 479 
with SMAPs (14,46,47), we did not observe any treatment-related adverse effects in mice. 480 
Importantly the control tumors were CIP2A positive, whereas tumors from DT-061 treated 481 
mice showed a clear trend for reduced CIP2A protein levels (Fig. S8C,D).  482 
 483 
Related to a potential link between SMAP response and CIP2A, western blot analyses 484 
revealed a surprising inhibition of CIP2A protein expression by SMAPs at 24 hours (Fig. 485 
6D,E and S8E-G). Indicative of transcriptional level regulation, CIP2A protein inhibition 486 
was accompanied with inhibition of CIP2A mRNA expression (Fig. 6F and S8G). The 487 
candidate mechanism for SMAP-elicited CIP2A inhibition was evaluated by studying the 488 
time course of CIP2A inhibition in relation to its two known upstream activators ERK and 489 
MYC (20,21,33), which both are inhibited by SMAPs (45). Whereas inhibition of ERK 490 
phosphorylation by SMAP preceded inhibition of CIP2A expression, MYC was inhibited in 491 
SMAP treated cells after CIP2A inhibition (Fig. 6G, and S8H).  492 
 493 
SMAPs, representing surrogate CIP2A inhibitors, were next tested for possible effects on 494 
biomarkers of CIP2A activity. Consistent with results in CIP2A-depleted cells (Fig. 4), 495 
SMAPs induced potent checkpoint signaling exemplified by phosphorylation of H2AX, ATR 496 
and CHK2 (Fig. 6H,I and S9A,B). SMAP treatment for 24 hours also resulted in potent 497 
inhibition of MYC protein expression (Fig. S9C). Regarding causality between SMAP-498 
induced checkpoint activation and CIP2A inhibition, SMAP-elicited CHK2 phosphorylation 499 
preceded CIP2A inhibition (Fig. S9D,F), whereas the ToPBP1-related p-ATR and H2AX 500 
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induction occurred only after CIP2A protein inhibition (Fig. 6J and S9D,E,G-H). 501 
Importantly, exogenous overexpression of CIP2A in MCF-10A cells, that were used to link 502 
the results to G2/M arrest (Fig. 1E), and TopBP1 effects (Fig. 4G,H), abrogated SMAP-503 
elicited H2AX induction (Fig. 6K and S9I). CIP2A overexpression also shifted the SMAP 504 
IC50 response in these cells (Fig. 6L). These results reveal that SMAPs have bi-phasic 505 
therapeutic activity consisting of direct PP2A activation (14,16), followed by transcriptional 506 
inhibition of CIP2A expression discovered here. SMAP-elicited CIP2A inhibition may thus 507 
halt the growth of BLBC cells by both prolonging the PP2A reactivation effects, but also via 508 
removing direct CIP2A-mediated direct effects on TopBP1 (Fig. 7). 509 
 510 
  511 
512 
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In this study, we provide comprehensive evidence that CIP2A overexpression can be a 515 
driver mechanism for BLBC initiation and malignant progression (Fig. 7). Consistent with 516 
the notion that even saturated genetic analysis of human breast cancers has failed to 517 
identify genetic BLBC driver, CIP2A gene sequence is not altered in BLBCs 518 
(https://cancer.sanger.ac.uk/cosmic). Instead, CIP2A expression is enhanced due to 519 
constitutive DNA-PK/CHK1 activity (48), TP53 inactivation (19), and EGFR pathway 520 
activation (20); which are all molecular hallmarks of BLBC (1,3)(Fig. 7). Transcriptional 521 
CIP2A induction early in DMBA-induced tumorigenesis is also fully supportive of its role in 522 
BLBC tumor initiation. Together these findings provide an explanation for high CIP2A 523 
expression in BLBC, whereas its newly discovered interaction with TopBP1 forms a 524 
molecular basis for its essential function in allowing malignant progression of DNA-525 
damaged mammary epithelial cells towards BLBCs.  526 
 527 
As opposed to previous assumptions that CIP2A is involved in the development of multiple 528 
human solid cancers (17), our results demonstrate selective involvement of CIP2A in 529 
initiation and progression of BLBCs both in human and mice. In addition to in vivo 530 
tumorigenesis results, in genetically defined cell culture models, only the Brca1/Trp53 531 
mutant basal-like cells were dependent on Cip2a for their colony growth. Also in human 532 
breast cancer samples, high CIP2A expression predicted for poor patient survival 533 
exclusively in BLBCs. The selectivity of CIP2A for BLBCs among the tumor types studied 534 
here, can be molecularly explained by the notion that CIP2A is able to coordinate BLBC 535 
hallmarks via promoting proliferative MYC and E2F1 activities, and at the same time 536 
blunting the G2/M checkpoint via its effects on the TopBP1/RAD51 complex (Fig. 7). In 537 
Research. 
on October 6, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 18, 2021; DOI: 10.1158/0008-5472.CAN-20-3651 
   
 
   
 
24 
addition to TopBP1, other highly CIP2A co-dependent DDR genes (Fig. 3A), not studied in 538 
this work, might confer its BLBC selectivity. One such candidate gene is POLQ (Fig. 3A, 539 
S4A,B), that is upregulated, and promotes genetic instability in BL-TNBC cells  (49).  540 
  541 
The functional homology of CIP2A with a number of critical DNA damage proteins (Fig. 542 
3A), is likely one of the most important contributions of this work for the future studies. This 543 
is supported by the recent results demonstrating essentiality of CIP2A in different DDR-544 
related genomic screens (40,50). Here we focused on validation of the novel interaction 545 
between nuclear CIP2A and TopBP1. Based on our results, TopBP1 can induce effective 546 
DDR in CIP2A deficient cells, whereas in CIP2A positive cells the TopBP1/RAD51 547 
complex chromatin recruitment is dampened allowing for continued mitotic activity (Fig. 548 
4K). This mechanism is fully in line with previous data related to TopBP1-mediated G2/M 549 
checkpoint regulation (5,7,9,11,43). As a notion, we validated the CIP2A function in 550 
TopBP1/RAD51 complex and in G2/M checkpoint activity in BRCA-proficient cells (Fig. 1E, 551 
4E-J, S5B-E). Whether the same mechanism is behind essentiality of CIP2A for HRD 552 
cells, including BRCA-deficient BLBC cells, remains to be studied. Importantly, in our 553 
model the enhanced TopBP1/RAD51 chromatin recruitment is due to loss of a direct and 554 
PP2A-independent CIP2A-TopBP1 interaction (Fig. 7). On the other hand, CIP2A can 555 
protect proteins in the TopBP1-associated complex from PP2A-mediated 556 
dephosphorylation as indicated with NBN S432 phosphorylation data (38). In addition, 557 
similar to other models (19,33,35), CIP2A inhibited dephosphorylation of both MYC and 558 
E2F1 in BLBC cells. CIP2A expression is in turn driven by MYC and E2F1 (19,33), and we 559 
postulate that these positive feedback loops have critical role in maintaining high 560 
proliferative activity in BLBC. Collectively, we conclude that CIP2A-mediated BLBC 561 
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initiation and progression results from a mixture of its PP2A-dependent and -independent 562 
effects (Fig. 7).  563 
 564 
In addition to identifying CIP2A as a driver candidate for BLBC, we demonstrate that 565 
SMAPs (14) function as transcriptional inhibitors of CIP2A expression. Our results reveal a 566 
model where SMAPs initially directly activate PP2A-B56 (14,16), and this followed by a 567 
prolonged PP2A activation due to transcriptional downregulation of CIP2A. Importantly, we 568 
were also able to demonstrate that CIP2A overexpression rescued the effects of SMAPs 569 
as assessed by both decreases in cell viability and H2AX regulation. However, it is 570 
important to note that we consider SMAPs as surrogate CIP2A inhibitors that also have 571 
acute effects not mediated by CIP2A inhibition, thereby explaining the anti-cancer effects 572 
of SMAPs noted in other cancer types (46,47). Importantly, we validated the therapeutic 573 
effects of three SMAPs across 15 different cell lines, including 6 individual patient-derived 574 
lines and a PDX model, together minimizing concerns related to compound specific 575 
effects, and known intratumoral heterogeneity of BLBC tumors.  576 
 577 
Together these results credential CIP2A as a driver protein for one of the most aggressive 578 
human cancer types, BLBCs. We also discover a novel link between CIP2A and DDR via 579 
direct interaction with TopBP1. Generally, these results emphasize the importance in 580 
characterizing proteome level signaling dysregulation in the cancer subtypes for which 581 
genetic drivers are lacking. 582 
  583 
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Figure legends: 758 
 759 
Figure 1. Cip2a knockout mice are selectively resistant to DMBA-induced mammary 760 
tumorigenesis. A, DMBA was orally administered to wild type (WT) and Cip2a-/- mice 761 
once a week for 6 consecutive weeks after which mice were monitored for signs of 762 
spontaneous tumor formation. B, Number of genetic variants in exons of the expressed 763 
genes in non-treated (control) and DMBA-treated WT (n=3) and Cip2a-/- (n=3) mouse 764 
mammary glands. P-value by Wilcoxon test. C, Incidences of tumor formation in different 765 
tissues in sacrificed DMBA-administered WT (n=18) and Cip2a-/- (n=14) mice. P-values 766 
between WT and Cip2a-/- groups calculated by Fisher’s exact test. D, Incidence of 767 
mammary tumors in WT (n=18) and Cip2a-/- (n=14) mice after starting administration of 768 
DMBA. P-value by log-rank test. E, Mitotic index analysis of MCF10A cells transfected with 769 
the indicated siRNAs. Cells were treated with 10Gy radiation dose and Nocodazole (100 770 
ng/ml) block 1 hour after IR for 18 hours. Mitotic cells were stained using phospho-histone 771 
H3 at Ser10. Scale bar: 100µm. Bar graph shows % of H3pS10 positive nuclei from three 772 
replicates, expressed as mean ± SD. F, Heat map of fraction of gene-trap insertions in the 773 
sense orientation compared to the total (sense and anti- sense) insertions in untreated 774 
HAP1 cells and HAP1 cells treated with successive low doses of IR (5x 1Gy). Color coding 775 
indicates essentiality of the indicated PP2A inhibitor protein for cell survival.  776 
 777 
Figure 2: Cip2a drives initiation of mouse BLBC-like tumors A, qRT-PCR analysis of 778 
Cip2a mRNA expression normalized to Actb and Gapdh from WT and Cip2a-/- non-treated 779 
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34 
(Ctrl) and DMBA-administered mouse non-tumorigenic mammary glands (MG), and from 780 
WT DMBA-induced mammary tumors. Shown is mean ± SD of 10 WT and 9 Cip2a-/- non-781 
treated mammary glands (Ctrl MG), 3 WT, and 3 Cip2a-/- mammary glands from DMBA-782 
administered mice, and 16 mammary tumors. P-values calculated by Mann-Whitney test. 783 
B, Representative images of immunohistochemical staining of Keratin-14 (K14), Keratin-8 784 
(K8), CIP2A, Ki67 and MYC proteins and hematoxylin and eosin (HE) from DMBA-induced 785 
mammary tumors from WT mice. Scale bar: 50μM C, Semiquantitative analysis of receptor 786 
status from 10 WT tumors. D, Top five enriched hallmark gene sets based on differentially 787 
regulated genes in non-tumorigenic Cip2a KO mouse mammary glands treated with six 788 
doses of DMBA. 789 
 790 
Figure 3: Co-dependence analysis reveals functional association of CIP2A with 791 
critical DNA damage response proteins A, Top 10 co-dependencies with CIP2A across 792 
739 cell lines genome-wide from CRISPR Avana screen. CIP2A’s own co-dependency 793 
rank for the top 10 genes is also listed. Data extracted from DepMap portal (Avana 794 
2020Q1). B, Genome-widely, CIP2A is the closest functional homologue to RHNO1 and 795 
TOPBP1. C, STRING functional protein association network analysis of CIP2A co-796 
dependent proteins from (A). By using the highest data confidence score (0.9), except for 797 
APEX2, DSCC1 and CIP2A, the other proteins form highly connected protein network. 798 
NBN phosphorylation indicated by red dot was found to be regulated by CIP2A based on 799 
(38). D, Top 10 Reactome pathways associated with genes from (A). E, Correlation 800 
between CIP2A and TOPBP1 mRNA expression across 1156 cell lines from Cancer Cell 801 
Line Encyclopedia. F, Pair-wise correlation of dependence of either BLBC or HGSOC cell 802 
lines of the indicated genes from DepMap portal (Avana 2020Q1). The values for BLBC 803 
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and HGSOC indicates correlation (max. 1) in dependence of the cells for the genes in the 804 
gene pair; the higher number indicating for higher similarity in the dependence. The color-805 
coded numbers indicate the difference in the co-dependence between BLBC and HGSOC 806 
cells for the indicated gene pair.  807 
 808 
Figure 4: CIP2A is an interacting partner of TopBP1 and promotes mitotic 809 
progression of DNA damaged cells. A, Schematic presentation of breast cancer cell line 810 
cDNA fragments coding for TopBP1 domains that interact with full length CIP2A in a yeast 811 
two-hybrid assay. Numbers in the TopBP1 drawing refer to BRCT domains 1-8; AAD, ATR 812 
activation domain. Analysis of the minimal common overlapping region between the 813 
TopBP1 fragments interacting with CIP2A reveal the TopBP1 aa. 829-853 as a candidate 814 
CIP2A interaction domain. B, Co-immunoprecipitation of endogenous CIP2A and ɣH2AX 815 
in HEK293 cells transiently overexpressing GFP or full length TopBP1-GFP as indicated. 816 
Input 5% of total IP. C, Co-immunoprecipitation of CIP2A in HEK293 cells transiently 817 
overexpressing V5-tagged CIP2A and GFP-tagged Empty vector (EV) or TopBP1 818 
truncated mutants T0, T1, T2, T3 as indicated in (D). Input 5% of total IP. D, Schematic 819 
representation of TopBP1 mutants used in (B,C) Relative interaction efficiencies are 820 
estimated from the experiment where all indicated mutants were included. E, Immortalized 821 
MCF10A cells transfected with non-targeting (SCR) or CIP2A siRNAs for 48hrs. 822 
Immunoblot of whole cell extracts (WCEs) probed for pATR, total ATR and CIP2A. Vinculin 823 
was used as a loading control. Relative quantifications of pATR/ATR and CIP2A plotted as 824 
Mean± SD from five replicates. F, MDA-MB-231 cells transfected with non-targeting (SCR) 825 
and CIP2A targeting siRNAs for 72 hrs and overexpressing TopBP1 mutants T0 and T1 as 826 
indicated for 48 hours. Immunoblot of WCEs probed for pATR, ɣH2AX and CIP2A. Actin 827 
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was used as a loading control. Relative quantifications of ɣH2AX plotted as Mean± SD 828 
from two replicates. G, IR-induced TopBP1 foci formation in MCF10A cells transfected with 829 
SCR or CIP2A siRNA as indicated for 48 hrs. Cells were treated with 5Gy radiation for 1 830 
hour and stained for CIP2A or TopBP1. H, Quantifications of the nuclear foci from (G) 831 
expressed as mean ± SD from representative experiment of three experiments with similar 832 
results I, IR-induced RAD51 foci formation in mouse mammary epithelial cells (MMECs) 833 
isolated from WT and Cip2a-/- mice cultured in-vitro for 48 hrs, treated with 5Gy radiation 834 
for 2 hours. J, Quantifications of the foci in expressed as mean ± SD of representative 835 
experiment. G-J, Images were taken at 63X on 3i spinning disk confocal and at least 150 836 
cells quantified per each condition using speckle counter pipeline on Cell Profiler. Scale 837 
bar: 10μM. E-J, All statistical analyses were conducted with Welch’s Student t-test for 838 
unequal variances, *p<0.05, ** p<0.01 K, Schematic presentation of the role of CIP2A in 839 
directly inhibiting TopBP1/RAD51-elicited G2/M checkpoint activation in non-transformed 840 
mammary epithelial cells.  841 
 842 
Figure 5: CIP2A is essential for survival of TP53/BRCA-mutant BLBC cells and 843 
drives proliferative signaling A, Expression of CIP2A mRNA in indicated molecular 844 
breast cancer subtypes. Data derived from TCGA. P-values by unpaired t-test.  B, 845 
Disease-free survival of CIP2A high (n=15) and CIP2A low (n=45) expressing basal-like 846 
TNBC patients in GSE21653 cohort. C, Disease-free survival of CIP2A high (n=45) and 847 
CIP2A low (n=132) expressing non-basal-like (HER2+, luminal A, luminal B and normal-848 
like) breast cancer patients in GSE21653 cohort. D, Overall survival of CIP2A high (n=12) 849 
and CIP2A low (n=51) basal-like TNBC patients in FinHer cohort. E, Overall survival of 850 
CIP2A high (n=17) and CIP2A low (n=47) non-basal like TNBC patients based IHC 851 
analysis from FinHer cohort. B-E, P-values calculated by log-rank test. F, CIP2A 852 
Research. 
on October 6, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 18, 2021; DOI: 10.1158/0008-5472.CAN-20-3651 
   
 
   
 
37 
dependence of breast cancer cell lines with CERES score < -0.4 from DepMap portal 853 
(Avana 2020Q1). Lower CERES scores indicate that the cell line is more dependent on 854 
CIP2A. Color coding indicates the breast cancer subtype of the cell line based on PAM50 855 
classification. G, Colony growth assays conducted on mammary tumor cell lines isolated 856 
from basal-type (KB1P#1 and KB1P#2: Brca1 and Trp53 mutant) and invasive lobular 857 
carcinoma (ILC)-type (KEP#1 and KEP#2: E-Cadherin and Trp53 mutant) mouse models; 858 
Cip2a was knocked out using CRISPR/Cas9 using 2 unique gRNAs. Western blots from 859 
the same samples probed for CIP2A below. Shown are representative images of at least 2 860 
independent biological repeats for each cell line. H, Summary of CIP2A-dependence on 861 
colony growth of indicated TP53-mutant TNBC cell lines transfected with Mock, non-862 
targeting siRNA (siSCR), or three unique CIP2A targeting siRNAs (siCIP2A #1, #2, #3). 863 
Colony areas were quantified and normalized to siSCR. I, Gene Set Enrichment Analysis 864 
(GSEA) conducted on differentially expressed genes obtained from RNA-seq of HCC38 865 
cells depleted with 3 unique CIP2A siRNAs. J, HCC38 cells transfected with SCR or 866 
CIP2A siRNAs for 72 hrs and immunoblotted for indicated protein.  867 
 868 
Figure 6: CIP2A targeting by SMAPs as potential BLBC therapy A, SMAP (DBK-1154) 869 
sensitivity profiles of eight BL-TNBC cell lines. Cell viabilities were measured using 870 
CellTiterGlo Luminescence Assay after 24 hrs of drug treatment. EC50s are listed in 871 
parentheses. B, Screening of patient-derived BLBC stem cell like cells for chemotherapy 872 
and SMAP responses. Heatmap indicates the drug sensitivity scores (DSS) of these cells 873 
across standard chemotherapeutics and three SMAPs DBK-1154, DT-061, NZ-1160). 874 
Higher DSS value indicates higher sensitivity. C, Tumor growth of an orthotopic patient 875 
derived xenograft model of basal triple negative breast cancer treated with DMA or 5mpk 876 
BID SMAP DT-061 for 43 days. Respective quantifications are represented as mean ± SD. 877 
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D,E, CIP2A western blots from MDA-MB-468 (D) and patient-derived stem cell-like cells, 878 
BCSC1 (E) on treatment with indicated SMAPs for 24h. DT-061 and DBK-1154 879 
concentration 20 µM. F, Kinetics of CIP2A mRNA expression from MDA-MB-468 cells after 880 
treatment with 20uM of DT-061. n=3 expressed as mean ± SD. G, Kinetics of pT202/Y204-881 
ERK, CIP2A and pS62-MYC from MDA-MB-468 cell line treated with SMAP DT-061 882 
(20uM) for indicated time points. Representative western blot data shown in Fig. S8H. n=3 883 
expressed as mean ± SD. H, Quantification of Western blots of MDA-MB-468 cell line 884 
treated with 20µM SMAP DT-061 for 24 hrs and probed for ɣH2AX, represented as mean 885 
± SD from n=3 replicates normalized to the untreated controls. I, Quantification of western 886 
blots from MDA-MB-468 cell line treated with 20uM of DT-061 for 24hrs, displayed in Fig. 887 
S9A. Data expressed as mean ± SD from n=3 replicates normalized to the untreated 888 
controls. J, Time course of CIP2A and ɣH2AX protein expression in MDA-MB-468 treated 889 
with DT-061 (20 µM) for indicated time periods. Western blot data are shown in Fig. S8F 890 
and S9B. K, CIP2A overexpression in MCF10A cell line rescues the SMAP-elicited ɣH2AX 891 
activation. Western blots of parental and CIP2A OE MCF10A cells treated with SMAP 892 
DBK-1154 for 24hrs and probed for ɣH2AX. GAPDH is used as loading control; ɣΗ2AX 893 
quantifications from n=4 replicates displayed below. L, Dose response curve of control and 894 
CIP2A OE stable cell line (CIP2A OE) MCF10A cells on treatment with concentration 895 
series of DBK-1154 for 24 hours. IC50 values indicated in parenthesis. A-L, p-values 896 
calculated using unpaired t-test, *P<0.05, **P<0.01, *** P<0.001, ****P<0.0001.  897 
 898 
Figure 7. Schematic presentation of the role for CIP2A in coordinating BLBC 899 
molecular hallmarks. The capacity of CIP2A to co-ordinately regulate G2/M checkpoint, 900 
and proliferative signaling by MYC and E2F1, provides a molecular basis for its role as 901 
BLBC driver. Black arrows indicate known mechanisms implicated in BLBC that either 902 
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regulate CIP2A expression and/or promote BLBC progression. Green arrows indicate 903 
PP2A inhibition-dependent mechanisms by which CIP2A increase proliferation capacity of 904 
BLBC cells. The PP2A-dependence of these mechanisms has been demonstrated 905 
previously (19,36). The orange block arrow indicates direct binding of CIP2A to TopBP1 906 
and inhibition of TopBP1-mediated checkpoint activity in response to DSB in premaligant 907 
mammary epithelial cells. Green block arrow indicates potential PP2A-dependent 908 
regulation of NBN phosphorylation. Collectively, CIP2A both responds to hallmarks of 909 
BLBCs (p53 inhibition, EGFR activity and HR defects) and co-ordinately controls the 910 
essential functional hallmarks; G2/M checkpoint and high proliferation activity. The 911 
relationship between CIP2A and BLBC hallmarks is also a plausible explanation for the 912 
selective role for CIP2A in BLBC as compared to other cancer types. 913 
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CIP2A's association
rank with the gene
1.   RHNO1 0.486 1
2.   H2AX 0.402 3
3.   TOPBP1 0.392 1
4.   MDC1 0.339 4
5.   POLQ 0.327 1
6.   NBN 0.315 1
7.   XRCC1 0.302 2
8.   APEX2 0.295 2
9.   PARP1 0.294 1
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Reactome pathways associated with CIP2A co-dependent genes
F
CRISPR Avana 2020 Q1 data from Depmap 
Pathway Description FDR
HSA-5693538 Homology Directed Repair 4.44E-14
HSA-5685939 HDR through MMEJ (alt-NHEJ) 1.47E-09
HSA-69473 G2/M DNA damage checkpoint 1.20E-08
HSA-5693607 Processing of DNA double-strand break ends 1.20E-08
HSA-5685938 HDR through Single Strand Annealing (SSA) 1.30E-05
HSA-5693616
Presynaptic phase of homologous DNA pairing and 
strand exchange 
1.38E-05
HSA-5693571 Nonhomologous End-Joining (NHEJ) 2.86E-05
HSA-5693565
Recruitment and ATM-mediated phosphorylation of 
repair and signaling proteins at DNA double strand 
breaks
3.82E-05
HSA-212436 Generic Transcription Pathway 7.47E-05
HSA-6804756 Regulation of TP53 Activity through Phosphorylation 1.00E-04
CIP2A vs. TOPBP1
mRNA expression (RNA-Seq RPKM):
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Figure 6
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